Paradigm Biopharmaceuticals Ltd - Asset Resilience Ratio

Latest as of June 2025: 0.00%

Paradigm Biopharmaceuticals Ltd (PAR) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Paradigm Biopharmaceuticals Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$0.00
≈ $0.00 USD Cash + Short-term Investments

Total Assets

AU$24.57 Million
≈ $17.39 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Paradigm Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See Paradigm Biopharmaceuticals Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Paradigm Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Paradigm Biopharmaceuticals Ltd (PAR) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Paradigm Biopharmaceuticals Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Paradigm Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Paradigm Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 1.39%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shanghai Shen Lian Biomedical Corp
SHG:688098
Biotechnology 3.87%

Annual Asset Resilience Ratio for Paradigm Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Paradigm Biopharmaceuticals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.00% AU$0.00
≈ $0.00
AU$24.57 Million
≈ $17.39 Million
--
2024-06-30 0.17% AU$46.20K
≈ $32.69K
AU$27.39 Million
≈ $19.38 Million
+0.10pp
2023-06-30 0.07% AU$46.20K
≈ $32.69K
AU$67.07 Million
≈ $47.46 Million
-0.02pp
2022-06-30 0.09% AU$46.20K
≈ $32.69K
AU$50.69 Million
≈ $35.87 Million
+0.04pp
2021-06-30 0.05% AU$46.20K
≈ $32.69K
AU$84.79 Million
≈ $60.00 Million
-0.61pp
2020-06-30 0.66% AU$746.20K
≈ $527.98K
AU$112.36 Million
≈ $79.50 Million
-6.94pp
2019-06-30 7.60% AU$6.50 Million
≈ $4.60 Million
AU$85.51 Million
≈ $60.50 Million
--
2017-06-30 0.00% AU$0.00
≈ $0.00
AU$14.35 Million
≈ $10.15 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$12.35 Million
≈ $8.74 Million
--
pp = percentage points

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology
Market Cap
$52.17 Million
AU$73.73 Million AUD
Market Cap Rank
#21738 Global
#778 in Australia
Share Price
AU$0.17
Change (1 day)
+3.03%
52-Week Range
AU$0.16 - AU$0.47
All Time High
AU$4.35
About

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more